Solid Tumor Study for Long Term Treatment of Cancer Patients Who Have Participated in BMS Parent Studies Investigating Adagrasib (BMS-986503)
Mirati Therapeutics Inc.
Summary
This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Participant is eligible to receive continued study treatment as per the parent study, and/or investigator assessed clinical benefit. * Individuals with assigned female sex at birth (AFSB) must have documented proof that they are not of childbearing potential. IOCBP participants who are sexually active must agree to follow the instructions for method(s) of contraception and included in the ICF. Exclusion Criteria: * Participant is not eligible for study treatment per the parent study eligibility criteria. * Participants who have completed treatment with the study drugs,…
Interventions
- DrugAdagrasib
Specified dose on specified days
- DrugPembrolizumab
Specified dose on specified days
- DrugCetuximab
Specified dose on specified days
- DrugPemetrexed
Specified dose on specified days
- DrugDocetaxel
Specified dose on specified days
- DrugIrinotecan
Specified dose on specified days
- DrugLeucovorin
Specified dose on specified days
Locations (30)
- Local Institution - 0005Phoenix, Arizona
- Local Institution - 0016Bellflower, California
- Local Institution - 0003Newark, Delaware
- Local Institution - 0001St. Petersburg, Florida
- Local Institution - 0064Chicago, Illinois
- Local Institution - 0017Rochester, Minnesota